Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal a subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Li, Qian ^a,c   Liu, Mei ^b   Ma, Fei ^a   Luo, Yang ^a   Cai, Ruigang ^a   Wang, Liming ^a   Xu, Ningzhi ^b   Xu, Binghe ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b CANCER HOSPITAL   (China)

^c PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; LET 7B; MICRORNA; MICRORNA 1274A; MICRORNA 1290; MICRORNA 194; MICRORNA 19A; MICRORNA 205; MICRORNA 28; MICRORNA 375; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN19 MICRORNA, HUMAN; MIRN205 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC IDENTIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VALIDATION PROCESS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLOOD; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; ROC CURVE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84923334405     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104870     Document Type: Article

References (32)

1. Coates AS, Colleoni M, Goldhirsch A (2012) Is adjuvant chemotherapy useful for women with luminal a breast cancer? J Clin Oncol 30: 1260-1263.
2. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070. (Pubitemid 41161233)
3. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, et al. (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8: R214.
4. Godfrey AC, Xu Z, Weinberg CR, Getts RC, Wade PA, et al. (2013) Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Breast Cancer Res 15: R42.
5. Kutanzi KR, Yurchenko OV, Beland FA, Checkhun VF, Pogribny IP (2011) MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics 2: 171-185.
6. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, et al. (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12: 320-327. (Pubitemid 37322062)
7. Hu Z, Dong J, Wang LE, Ma H, Liu J, et al. (2012) Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis 33: 828-834.
8. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(2Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
9. Qi R, Weiland M, Gao XH, Zhou L, Mi QS (2012) Identification of endogenous normalizers for serum microRNAs by microarray profiling: U6 small nuclear RNA is not a reliable normalizer. Hepatology 55: 1640-1642; author reply 1642-1643.
10. Hu X, Guo J, Zheng L, Li C, Zheng TM, et al. (2013) The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Mol Cancer Res 11: 240-250.
11. Quesne JL, Jones J, Warren J, Dawson SJ, Ali HR, et al. (2012) Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue. J Pathol 227: 306-314.
12. Farazi TA, Ten Hoeve JJ, Brown M, Mihailovic A, Horlings HM, et al. (2014) Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. Genome Biol 15: R9.
13. Liang Z, Li Y, Huang K, Wagar N, Shim H (2011) Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res 28: 3091-3100.
14. Markou A, Yousef GM, Stathopoulos E, Georgoulias V, Lianidou E (2014) Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up. Clin Chem 60: 197-205.
15. Sochor M, Basova P, Pesta M, Dusilkova N, Bartos J, et al. (2014) Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer 14: 448.
16. Ye XM, Zhu HY, Bai WD, Wang T, Wang L, et al. (2014) Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC Cancer 14: 134.
17. von Minckwitz G, Loibl S, Maisch A, Untch M (2011) Lessons from the neoadjuvant setting on how best to choose adjuvant therapies. Breast 20 Suppl 3: S142-145.
18. Hayes DF (2012) Targeting adjuvant chemotherapy: a good idea that needs to be proven! J Clin Oncol 30: 1264-1267.
19. Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R, et al. (2012) Systemic mirnas as potential biomarkers for malignancy. Int J Cancer 131: 2215-2222.
20. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, et al. (2012) Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118: 2603-2614.
21. Sun Y, Wang M, Lin G, Sun S, Li X, et al. (2012) Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One 7: e47003.
22. Wang H, Tan G, Dong L, Cheng L, Li K, et al. (2012) Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 7: e34210.
23. Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, et al. (2010) Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer 116: 1431-1439.
24. von Minckwitz G, Untch M, Loibl S (2013) Update on neoadjuvant/ preoperative therapy of breast cancer: experiences from the German Breast Group. Curr Opin Obstet Gynecol 25: 66-73.
25. Peltier HJ, Latham GJ (2008) Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 14: 844-852. (Pubitemid 351574906)
26. Choi BH, Kim CG, Lim Y, Shin SY, Lee YH (2008) Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett 259: 111-118. (Pubitemid 350235095)
27. Lee JT Jr., Steelman LS, McCubrey JA (2004) Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 64: 8397-8404. (Pubitemid 39491779)
28. Takada T, Suzuki H, Gotoh Y, Sugiyama Y (2005) Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab Dispos 33: 905-909. (Pubitemid 41002770)
29. Mo WC, Zhang ZJ, Liu Y, Bartlett PF, He RQ (2013) Magnetic shielding accelerates the proliferation of human neuroblastoma cell by promoting G1-phase progression. PLoS One 8: e54775.
30. Wu H, Zhu S, Mo YY (2009) Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 19: 439-448.
31. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, et al. (2007) Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67: 11612-11620.
32. Yao Y, Chen S, Zhou X, Xie L, Chen A (2014) 5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cells. Oncol Lett 7: 541-547.